GlucoTrack, Inc. (GCTK) fell sharply on Thursday, dropping 25.26 percent, or $0.86, to trade at $2.54, despite the company announcing the issuance of three new U.S. patents covering its continuous blood glucose monitoring platform.
The medical device company said the patents strengthen its intellectual property around its fully implantable, multi-year continuous blood glucose monitoring system, including sensor chemistry, intravascular lead design, and low-power electronics, as it advances toward commercialization.
The stock opened at $3.38 after a previous close of $3.41 and traded in a wide range between $2.33 and $3.44 during the session on the Nasdaq. The bid was $2.73 and the ask $3.01.
Trading volume surged to about 13.38 million shares, far above the average volume of 84,247. GlucoTrack's 52-week range is $2.33 to $127.80.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.